IRIS PubliCatt

Miele, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.809
NA - Nord America 6.054
AS - Asia 2.868
SA - Sud America 90
AF - Africa 41
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 22
Totale 16.914
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.001
DE - Germania 2.454
SE - Svezia 1.510
IT - Italia 1.364
CN - Cina 1.018
SG - Singapore 1.007
IE - Irlanda 558
UA - Ucraina 492
ID - Indonesia 364
FR - Francia 234
FI - Finlandia 232
GB - Regno Unito 219
RU - Federazione Russa 210
NL - Olanda 159
TR - Turchia 146
IN - India 134
BE - Belgio 87
BR - Brasile 69
HK - Hong Kong 62
PL - Polonia 58
CH - Svizzera 50
AT - Austria 49
IR - Iran 42
CZ - Repubblica Ceca 40
CA - Canada 34
JP - Giappone 27
AU - Australia 25
CI - Costa d'Avorio 21
EU - Europa 19
PT - Portogallo 15
ES - Italia 14
RO - Romania 13
LT - Lituania 11
GR - Grecia 8
MX - Messico 8
KR - Corea 7
VN - Vietnam 7
CL - Cile 6
DK - Danimarca 6
HU - Ungheria 6
IL - Israele 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
AR - Argentina 5
BZ - Belize 5
CO - Colombia 5
EG - Egitto 5
KG - Kirghizistan 5
NZ - Nuova Zelanda 5
LK - Sri Lanka 4
NG - Nigeria 4
PH - Filippine 4
PK - Pakistan 4
EE - Estonia 3
HR - Croazia 3
IQ - Iraq 3
MY - Malesia 3
PA - Panama 3
A2 - ???statistics.table.value.countryCode.A2??? 2
DZ - Algeria 2
IS - Islanda 2
KH - Cambogia 2
NO - Norvegia 2
PR - Porto Rico 2
RE - Reunion 2
SC - Seychelles 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UZ - Uzbekistan 2
VA - Santa Sede (Città del Vaticano) 2
A1 - Anonimo 1
AL - Albania 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
DJ - Gibuti 1
EC - Ecuador 1
GT - Guatemala 1
KZ - Kazakistan 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
PE - Perù 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
TJ - Tagikistan 1
UY - Uruguay 1
ZA - Sudafrica 1
Totale 16.914
Salva come PNG Salva come JPEG
Città #
Chandler 1.092
Singapore 743
Dublin 558
Ashburn 508
Jakarta 361
Chicago 316
Jacksonville 287
San Mateo 251
Rome 248
Milan 213
Nanjing 204
New York 202
Moscow 158
Nürnberg 154
Ann Arbor 153
Wilmington 148
Boston 141
Helsinki 125
Izmir 123
Houston 122
Marseille 115
Los Angeles 113
Princeton 113
Munich 111
Dearborn 107
Beijing 105
Cattolica 104
Brussels 86
Woodbridge 86
Nanchang 77
Seattle 75
Boardman 71
Nuremberg 56
Hong Kong 55
Redmond 55
Kraków 50
Fairfield 49
Redwood City 47
Hebei 45
Tianjin 42
Shenyang 41
Zurich 40
Bremen 38
Lawrence 38
Brno 34
Kunming 34
Zhengzhou 34
Guangzhou 33
Mountain View 30
Norwalk 30
Changsha 29
London 28
San Jose 27
Fremont 24
Shanghai 24
Falkenstein 23
Hangzhou 23
Pune 23
Jiaxing 22
Santa Clara 22
University Park 22
Abidjan 21
Vienna 21
Washington 21
Frankfurt am Main 19
Trieste 19
Augusta 18
Paris 18
Toronto 18
Andover 17
Castelnuovo di Val di Cecina 17
Jinan 17
San Diego 17
Cambridge 16
Kish 16
Leawood 16
Portland 16
Stockholm 16
Palermo 15
Lanzhou 14
Rio de Janeiro 14
Busto Arsizio 13
Falls Church 13
Lancaster 13
Ningbo 13
Atlanta 12
Tokyo 12
Amsterdam 11
Boydton 11
Chongqing 11
Lappeenranta 11
Ottawa 11
Simi Valley 11
Naples 10
Phoenix 10
Taizhou 10
Dallas 9
Hefei 9
San Francisco 9
Campagna 8
Totale 8.841
Salva come PNG Salva come JPEG
Nome #
A multi-society Delphi consensus statement on new fatty liver disease nomenclature 478
Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging 396
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 213
A phase II study of sunitinib in advanced hepatocellular carcinoma 209
13C-methionine breath tests for mitochondrial liver function assessment. 204
13C-breath tests in the study of microsomal liver function 195
gc) Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. 188
-Hepatic steatosis and vascular disease 172
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 162
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 160
Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver 155
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 155
134C-breath tests in the study of mitochondrial liver function 154
Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. 150
Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms 147
Effect of sildenafil on diabetic gastropathy. 143
13C-breath tests in the study of microsomial liver function 142
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 141
Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm 136
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 130
13C-methionine breath tests for mitochondrial liver function assessment 128
The Effect of CYP, GST, and SULT Polymorphisms and Their Interaction with Smoking on the Risk of Hepatocellular Carcinoma 125
Assessment of neurological manifestations in hospitalized patients with COVID-19 124
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 124
[Oxidative stress in metabolic syndrome and nonalcoholic steatohepatitis. Is it possible a role for vitamins in clinical practice?] 121
Potential use of liver function breath tests in the clinical practice. 121
gc) Celiac disease in the 21st century: issues of under- and over-diagnosis 118
[Helicobacter pylori infection: from gastric to systemic disease] 117
Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival 117
13C-breath tests in the study of mitochondrial liver function 114
[The treatment of hepatocellular carcinoma: an update] 108
gastroesophageal reflux disease: facts and uncertaines 107
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 107
-Fatty liver and drugs 106
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 105
Tromboembolism and breast cancer: the hidden risk for patient and physician 104
A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease 104
Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). 103
Cryoglobulinemia: a true internistic disease? 102
Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis 102
Intrafamilial transmission of hepatitis C virus in Italy: a systematic review 102
Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. 102
Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. 100
Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease 100
An Attempt of Specific Desensitizing Treatment with Gliadin in Coleliac Disease 98
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 97
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 97
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 96
Liver transplantation in patients with alcoholic liver disease: A retrospective study 96
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome 90
-Nonalcoholic fatty liver disease: defining a common problem 89
High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study 89
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. 88
Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease 88
Alcoholic and nonalcoholic forms of fatty liver disease. 87
Gallstone disease is associated with more severe liver damage in patients with non-alcoholic Fatty liver disease 87
Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets 87
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 84
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target 83
Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk 83
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial 82
Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1) 82
Braised liver with herbs: the risks of naturopathic hepatoprotection. 81
Gender affects 13C-ketoisocaproic acid breath test 80
A case of variant angina in a patient under chronic treatment with sorafenib 79
Socio-demographic determinants of coinfections by HIV, hepatitis B and hepatitis C viruses in central Italian prisoners. 78
Impact of new DAA therapy on real clinical practice: A multicenter region-wide cohort study 78
A giant calcified hepatic mass 77
Is coeliac disease a confounding factor in the diagnosis of NASH? 76
Drug-induced hepatitis 76
Review article: breath testing for human liver function assessment. 76
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 76
The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: A pilot study 76
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 73
Impairment of recent thymic emigrants in HCV infection. 72
A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease 72
Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH) 71
Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind 71
Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting 71
COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel 71
Mediterranean diet and the prevention of non-alcoholic fatty liver disease: Results from a case-control study 71
Reverse time-dependent effect of alphafetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma 70
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 69
NON ALCOHOLIC STEATOHEPATITIS (NASH) INDUCED BY CARBAMAZEPINE AND VARIEGATE PORPHYRIA 68
anticholinergic syndrome due to " Devil's herb': when risks come from the ancient time 68
Focus on fatty liver in clinical practice 67
Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome 67
Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 67
A case of esomeprazole-induced transient diabetes and hepatitis: the role of liver inflammation in the pathogenesis of insulin resistance 66
NAFLD and NASH: behind the fat, there's something more. 66
"tear-drop shaped" HCC 65
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 65
Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of Sorafenib 65
Sporadic HEV hepatitis in Italy. 64
Diabetes and Insulin Therapy, but Not Metformin, Are Related to Hepatocellular Cancer Risk 64
Propafenone-related cholestatic hepatitis in an elderly patient. 64
When was celiac disease born?: the Italian case from the archeologic site of Cosa 63
High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection 62
Liver transplantation in alcoholic patients: Impact of an alcohol addiction unit within a liver transplant center 62
Acute HEV hepatitis: clinical and laboratory diagnosis 61
Totale 10.762
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.854
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.854
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020569 0 0 0 0 0 0 0 72 97 144 130 126
2020/20211.172 61 116 54 123 156 52 127 21 151 67 218 26
2021/20221.565 46 112 49 178 111 35 24 235 57 98 295 325
2022/20234.190 436 420 240 452 424 566 283 334 448 271 237 79
2023/20243.105 238 803 111 177 160 337 226 106 45 216 266 420
2024/20252.615 151 124 529 245 557 305 345 359 0 0 0 0
Totale 17.298